February 11, 2016
2 min read
Save

Autologous, nonmyeloablative HSCT show promise for advanced multiple myeloma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A frontline transplant tandem approach consisting of autologous and nonmyeloablative allogeneic transplantation demonstrated promising OS and PFS among patients with multiple myeloma, according to phase 2 study results.

Although new drug therapies and autologous hematopoietic stem cell transplantation have improved outcomes for multiple myeloma, the condition remains largely incurable, according to study background.

“Allogeneic HSCT represents a potential curative option for multiple myeloma patients,” Jean Roy, MD, associate professor of medicine at University of Montreal and department head of hematology and oncology at Maisonneuve-Rosemont Hospital, and colleagues wrote. “Early studies using myeloablative regimens in patients with advanced disease have reported a PFS range from 34% to 70% at 4 years to 6 years in those achieving complete remission after allogeneic transplant. Factors associated with improved PFS included fewer treatments before transplant, grade I acute graft-versus-host disease [GVHD] and presence of chronic GVHD.”

However, myeloablative HSCT appeared associated with a higher incidence of nonrelapse mortality, according to the researchers.

Thus, to maximize the anti-myeloma effect and minimize nonrelapse mortality, Roy and colleagues developed a nonmyeloablative regimen associated with a high incidence of chronic GVHD.

The analysis included data from 92 newly diagnosed patients (median age, 52 years; range, 39-64; 57% men) treated between 2001 and 2010. Each patient underwent autologous HSCT. Sixty to 100 days later, the patients underwent an outpatient nonmyeloablative allogeneic HSCT from a 6/6 HLA-matched sibling donor with fludarabine and cyclophosphamide conditioning.

Median follow-up was 8.8 years.

The researchers observed classical acute GVHD in 9% of patients (95% CI, 4-17).

Patients treated with the combined autologous and nonmyeloablative regimens experienced a 10-year PFS probability of 41% (95% CI, 30-52; median, 4.3 years). The 10-year OS probability was 62% (95% CI, 51-72; median not reached).

Despite a high cumulative incidence of chronic GVHD (79%), the majority of long-term survivors discontinued immunosuppressive drugs by 5 years after treatment. Among survivors, the probability of being on any systemic immunosuppressive treatment at 5 years was 38% (95% CI, 27-49); by 10 years, it was 22% (95% CI, 7-39).

The 10-year incidence of nonrelapse mortality was 10% (95% CI, 4-18).

Ten patients died of causes other than multiple myeloma, including refractory GVHD (n = 6), lung cancer (n = 3, including one smoker) and invasive aspergillosis (n = 1).

“In many hospitals, doctors have abandoned the use of allografts for multiple myeloma due to the risk for toxicity and relapse,” Roy said in a press release. “Our results, on the other hand, have led us to offer the treatment to more patients, especially younger patients and those with poorer prognoses.” – by Cameron Kelsall

Disclosure: The researchers report no relevant financial disclosures.